Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$11.60 -1.8%	$11.08	$7.58 ▼ $19.77	$439.29M	0.38	284,318 shs	187,305 shs
EBS Emergent Biosolutions	$6.27 -0.6%	$5.83	$4.02 ▼ $15.10	$340.44M	2.1	1.77 million shs	2.48 million shs
ELTX Elicio Therapeutics	$8.05 +1.1%	$0.00	$0.00 ▼ $0.00	$128.78M	1.14	59,504 shs	288,710 shs
SAGE Sage Therapeutics	$9.30 +1.9%	$7.20	$4.62 ▼ $13.47	$582.37M	0.18	1.27 million shs	2.60 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	-4.21%	+11.11%	+7.01%	-27.18%
EBS Emergent Biosolutions	0.00%	+0.11%	-2.00%	+9.36%	-3.80%
ELTX Elicio Therapeutics	0.00%	+5.92%	+56.31%	-8.00%	+20.51%
SAGE Sage Therapeutics	0.00%	+38.81%	+42.42%	+13.28%	-16.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELC Celcuity	1.1657 of 5 stars	3.6	0.0	0.0	0.0	2.5	0.0
EBS Emergent Biosolutions	4.2657 of 5 stars	3.5	2.0	4.6	1.5	2.5	1.3
ELTX Elicio Therapeutics	1.1997 of 5 stars	2.5	3.0	0.0	0.0	1.7	0.6
SAGE Sage Therapeutics	2.9406 of 5 stars	2.0	1.0	4.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	3.17	Buy	$30.80	165.52% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	128.53% Upside
ELTX Elicio Therapeutics	3.00	Buy	$10.00	24.22% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.94% Downside

Current Analyst Ratings Breakdown

Latest ELTX, CELC, SAGE, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/19/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/15/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/11/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
4/2/2025	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	$3.11 per share	N/A
EBS Emergent Biosolutions	$1.04B	0.33	$1.94 per share	3.24	$8.91 per share	0.70
ELTX Elicio Therapeutics	$2.30M	56.00	N/A	N/A	($1.03) per share	-7.82
SAGE Sage Therapeutics	$41.24M	14.12	N/A	N/A	$7.60 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$111.78M	-$3.03	N/A	N/A	N/A	N/A	-96.21%	-49.44%	8/13/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.03	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
ELTX Elicio Therapeutics	-$51.90M	-$6.95	0.00	N/A	N/A	N/A	N/A	-185.70%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest ELTX, CELC, SAGE, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CELC Celcuity	-$0.95	-$0.86	+$0.09	-$0.86	N/A	N/A
5/13/2025	Q1 2025	ELTX Elicio Therapeutics	-$0.67	-$0.87	-$0.20	-$0.87	N/A	N/A
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/31/2025	Q4 2024	CELC Celcuity	-$0.72	-$0.85	-$0.13	-$0.85	N/A	N/A
3/31/2025	Q4 2024	ELTX Elicio Therapeutics	-$0.94	-$1.02	-$0.08	-$1.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	1.14	6.61	6.61
EBS Emergent Biosolutions	1.20	6.32	3.51
ELTX Elicio Therapeutics	N/A	1.83	1.83
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
EBS Emergent Biosolutions	78.40%
ELTX Elicio Therapeutics	35.03%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
CELC Celcuity	15.78%
EBS Emergent Biosolutions	3.20%
ELTX Elicio Therapeutics	28.65%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	37.87 million	31.89 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	52.54 million	Optionable
ELTX Elicio Therapeutics	N/A	16.00 million	11.41 million	Not Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

ELTX, CELC, SAGE, and EBS Headlines

Recent News About These Companies

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22 at 8:25 PM | msn.com

Robert W. Baird Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 21 at 1:57 AM | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20 at 9:56 AM | marketbeat.com

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

June 20 at 9:21 AM | mmm-online.com

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19, 2025 | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19, 2025 | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18, 2025 | biospace.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18, 2025 | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17, 2025 | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17, 2025 | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.com

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17, 2025 | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 17, 2025 | pharmaphorum.com

Supernus makes depression drug play with $795m Sage buyout

June 17, 2025 | msn.com

Sage, following Setbacks, to sell to Supernus for $561M

June 17, 2025 | biopharmadive.com

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

June 17, 2025 | fiercepharma.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, CELC, SAGE, and EBS Company Descriptions

Celcuity NASDAQ:CELC

$11.60 -0.21 (-1.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$11.62 +0.02 (+0.13%)

As of 06/20/2025 05:45 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Emergent Biosolutions NYSE:EBS

$6.27 -0.04 (-0.60%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$6.40 +0.13 (+2.04%)

As of 06/20/2025 06:51 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Elicio Therapeutics NASDAQ:ELTX

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Sage Therapeutics NASDAQ:SAGE

$9.30 +0.17 (+1.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.17 -0.13 (-1.40%)

As of 06/20/2025 07:57 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time